RxDoctor Payments Data

Timothy Rabe, DO

Internal Medicine · Pittsburgh, PANPI 1023514874

Payments from drug & device makers

$2,599in general payments, 2019–2025

Across 162 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$462
  • GSK$435
  • Amgen$340
  • AstraZeneca$337
  • Lilly USA, LLC$222
  • Corcept Therapeutics$159
  • plus $644 from 13 others

What the payments were for

  • Food & beverage$2,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,599 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,939
Medicare patients
142
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide172$197,574
JardianceEmpagliflozin238$196,281
EliquisApixaban179$167,910
RybelsusSemaglutide75$107,121
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$63,566
XareltoRivaroxaban48$58,657
JanuviaSitagliptin Phosphate71$58,353
TrulicityDulaglutide42$47,840
FarxigaDapagliflozin Propanediol33$47,381
TradjentaLinagliptin55$45,309
LinzessLinaclotide67$44,952
MounjaroTirzepatide39$43,166
Synjardy XrEmpagliflozin/Metformin Hcl59$39,812
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog33$39,709
InvokanaCanagliflozin44$30,790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$462$304,695247 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat$147$291,913366 claims
PfizerEliquis, Nurtec Odt$14$198,300197 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix$435$95,580135 claims
Lilly USA, LLCTrulicity, Mounjaro$222$91,00681 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$337$83,64993 claims
MerckJanuvia, Janumet$11$64,09983 claims
AbbVieLinzess, Restasis$153$53,39578 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →